Clofazimine

Brand names: Lamprene · Active ingredient: Clofazimine

In short: LAMPRENE is indicated in combination with other anti-leprosy drugs for the treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy, and lepromatous leprosy complicated by erythema nodosum leprosum. To prevent the development of drug-resistance, LAMPRENE should be used only

Forms & strengthsCapsules: 50 mg, brown opaque spherical soft gelatin capsule.
LabelNovartis Pharmaceuticals Corporation
Label updatedAug 18, 2026

What is Clofazimine used for?

LAMPRENE is indicated in combination with other anti-leprosy drugs for the treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy, and lepromatous leprosy complicated by erythema nodosum leprosum.

To prevent the development of drug-resistance, LAMPRENE should be used only as a part of combination therapy for initial treatment of lepromatous (multibacillary) leprosy .

For further guidance on the treatment of leprosy, contact the National Hansen’s Disease Clinical Center, Baton Rouge, Louisiana (LA) at (1-800-642-2477) or http://www.hrsa.gov/hansensdisease/clinicalcenter.html.

Clofazimine dosage

Dapsone-sensitive Lepromatous (multibacillary) Leprosy

Administer 100 mg (two 50 mg capsules) of LAMPRENE daily with meals in combination with two other anti-leprosy drugs for at least 2 years and if possible, until negative skin smears are obtained, followed by monotherapy with an appropriate anti-leprosy drug.

Dapsone-resistant Lepromatous Leprosy

Administer 100 mg (two 50 mg capsules) of LAMPRENE daily with meals in combination with one or more other anti-leprosy drugs for 3 years, followed by monotherapy with 100 mg (two 50 mg capsules) of LAMPRENE daily.

Lepromatous Leprosy complicated by Erythema Nodosum Leprosum Reactions

Administer LAMPRENE at 100 mg (two 50 mg capsules) to 200 mg (four 50 mg capsules) daily, in conjunction with baseline anti-leprosy treatment and steroids as clinically indicated. If LAMPRENE is administered at 200 mg (four 50 mg capsules) dose, taper to 100 mg (two 50 mg capsules) as soon as possible after the erythema nodosum reaction is controlled. Doses of LAMPRENE of more than 100 mg daily should be given for as short a period as possible and only under close medical supervision .

Sexually-active females of reproductive potential should have a pregnancy test prior to LAMPRENE administration .

How to take Clofazimine — instructions & advice from the label

Information for Patients

Inform patients to take LAMPRENE with meals.

Inform patients to report abdominal pain or other gastrointestinal symptoms, such as nausea or vomiting, to their healthcare provider.

Inform patients that LAMPRENE frequently causes a red to brownish-black discoloration of the skin as well as discoloration of the conjunctivae, tears, sweat, sputum, urine, and feces. Advise patients that skin discoloration may take several months or years to resolve after the conclusion of therapy with LAMPRENE.

Inform patients that skin discoloration may result in psychological effects and advise them to report any symptoms of depression or suicidal ideation.

Advise females of reproductive potential to use effective contraception while taking LAMPRENE and for at least 4 months after stopping treatment with LAMPRENE. It is also recommended that they have a pregnancy test prior to starting treatment with LAMPRENE.

Advise males taking LAMRENE to use a condom during intercourse while taking LAMPRENE and for at least 4 months after stopping treatment.

Inform patients of the importance of compliance with the prescribed drug regimen in order to prevent drug resistance. …

Warnings & precautions

Do not take this medicine if: LAMPRENE is contraindicated in patients with known hypersensitivity to clofazimine or any of the excipients of LAMPRENE.

Clofazimine may accumulate in various organs as crystals, including the mesenteric lymph nodes and histiocytes at the lamina propria of the intestinal mucosa, spleen and liver. Deposition in the intestinal mucosa may lead to intestinal obstruction that may necessitate exploratory laparotomy. Splenic infarction, gastrointestinal bleeding, and death have been reported. If a patient complains of pain in the abdomen, nausea, vomiting, or diarrhea, initiate appropriate medical investigations and reduce the daily dose of LAMPRENE, or increase the dosing interval or discontinue the drug. Doses of LAMPRENE of more than 100 mg daily should be given for as short a period as possible (less than 3 months) and only under close medical supervision.

Cases of Torsade de Pointes with QT prolongation have been reported in patients receiving dosage regimens containing higher than 100 mg daily dose of LAMPRENE or in combination with QT prolonging medications. For QT prolongation and Torsade de Pointes cases, the patient must remain under medical surveillance. In all these patients, monitor electrocardiograms (ECGs) for QT prolongation and cardiac rhythm disturbances .

QT prolongation has also been reported in patients who were receiving concomitant LAMPRENE and bedaquiline at the recommended dosages. Monitor ECGs in patients taking LAMPRENE and bedaquiline concomitantly, and discontinue LAMPRENE if clinically significant ventricular arrhythmia is noted or if the QTcF interval is 500 ms or greater. If syncope occurs, obtain an ECG to detect QT prolongation.

LAMPRENE causes orange-pink to brownish-black discoloration of the skin, as well as discoloration of the conjunctivae, tears, sweat, sputum, urine and feces in 75%-100% of patients. …

Clofazimine side effects

The following serious adverse reactions are discussed in greater detail in other sections of the labeling:

Abdominal Obstruction and Gastrointestinal Adverse Reactions

QT Prolongation

Skin and Body Fluid Discoloration and Other Skin Reactions

Psychological Effects of Skin Discoloration

The following adverse reactions associated with the use of LAMPRENE were identified. Because these adverse reactions are reported from different studies, these adverse reactions cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Adverse Reactions Occurring In More Than 1% of Patients

Skin: Pigmentation from pink to brownish-black in 75% to 100% of the patients within a few weeks of treatment; ichthyosis and dryness (8% to 28%); rash and pruritus (1% to 5%).

Gastrointestinal: Abdominal and epigastric pain, diarrhea, nausea, vomiting, gastrointestinal intolerance (40% to 50%).

Ocular: Diminished vision, conjunctival and corneal pigmentation due to clofazimine crystal deposits; dryness; burning; itching; irritation.

Other: Discoloration of urine, feces, sputum, sweat; elevated blood sugar; elevated erythrocyte sedimentation rate (ESR).

Adverse Reactions Occurring In Less Than 1% of Patients

Skin: Phototoxicity, erythroderma, acneiform eruptions, monilial cheilosis. …

Drug interactions

Concomitant use of LAMPRENE may increase concentrations of drugs that are substrates of CYP3A4/5 which may increase the risk of toxicity of these drugs. Monitor for toxicities of these drugs when used concomitantly with LAMPRENE.

QT prolongation and Torsade de Pointes have been reported in patients receiving LAMPRENE in combination with QT prolonging medications, such as bedaquiline. Monitor ECGs for QT prolongation when LAMPRENE is administered with other drugs known to prolong the QT interval .

About this medicine

LAMPRENE (clofazimine) is an antimycobacterial available as soft gelatin capsules for oral administration. Each capsule contains 50 mg of micronized clofazimine suspended in an oil-wax base. Clofazimine is a substituted iminophenazine bright-red dye. Its chemical name is 3-(p-chloroanilino)-10-(p-chlorophenyl)-2, 10-dihydro-2-isopropyliminophenazine, and its structural formula is

Clofazimine is a reddish-brown powder. It is slightly soluble in acetic acid, dimethylformamide, chloroform and ether; very slightly soluble in ethanol and acetonitrile; soluble in methylene chloride. Its molecular weight is 473.4 g/mol. Its molecular formula is C27H22Cl2N4.

The Inactive Ingredients

Capsules fill: Anhydrous citric acid, Butylated hydroxytoluene, Fully hydrogenated rapeseed oil, Hydrogenated soybean oil, Lecithin, Partially hydrogenated soybean oil, Propylene glycol, Yellow wax. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 2e07448f-f888-4747-80ab-570c1b621250. Read the full official label on DailyMed.